Summary of Key Points from the Conference Call Company Overview - The company discussed its performance for 2025 and provided guidance for 2026, indicating a strong growth trajectory in various business segments, particularly in the chemical macromolecule and emerging business sectors [2][3][16]. Financial Performance - In 2025, the company achieved a revenue of 6.67 billion yuan, a year-on-year increase of 14.9%, aligning with the growth guidance of 13%-15% [3][16]. - The adjusted net profit for 2025 was 1.253 billion yuan, reflecting a growth of over 50% compared to 2024 [3][16]. - The gross profit margin for 2025 was stable at 42%, with a net profit margin of 17%, up by 0.6 percentage points [3][16]. Order Backlog and Growth - As of Q1 2026, the company had an order backlog of 1.385 billion USD, a 31.7% increase year-on-year, driven primarily by the macromolecule business [2][3][16]. - The fourth quarter of 2025 saw a significant increase in orders, marking the highest growth rate in five quarters, attributed to new business orders [2][20]. Business Segment Performance Small Molecule Business - Revenue for the small molecule segment in 2025 was 4.735 billion yuan, a 3.6% increase, with a gross margin of 46.8% [4][6]. - The company is involved in five GLP-1 clinical projects, with two in late-stage development [6][20]. Emerging Business - The emerging business segment generated 1.929 billion yuan in revenue, a 57.3% increase, with a gross margin of 30.1%, up 8 percentage points from 2024 [4][6]. - Revenue from overseas markets in this segment grew by 240% [4][6]. Chemical Macromolecule Business - This segment saw a revenue increase of 123% to 1.028 billion yuan, with a backlog growth of 127.6% [4][6]. - The company is servicing 19 GLP-1 clinical projects, with eight in late-stage development [6][15]. Biopharmaceutical CDMO - The biopharmaceutical CDMO business nearly doubled its revenue to 294 million yuan, with a 55.6% increase in order backlog [9][10]. - The first ADC commercial workshop is expected to be delivered in Q2 2026 [10]. Capital Expenditure and Capacity Expansion - The company plans to invest 2.1 billion yuan in capital expenditures for 2026, with 70%-80% directed towards new business segments [2][19]. - The production capacity for solid-phase peptide synthesis is expected to expand to 69,000 liters by the end of 2026 [2][19]. Market Trends and Challenges - The company noted that the recent Middle East conflict has led to price increases in raw materials, but the overall impact on costs is manageable [17][18]. - There is a growing demand for new modalities in the CDMO market, particularly in conjugated drugs and peptides, indicating a positive outlook for future orders [21][22]. Outlook for 2026 - The company expects revenue growth of 19%-22% for 2026, with an additional 2-3 percentage points expected from constant currency adjustments [2][16]. - The gross margin for the emerging business is anticipated to improve further due to increased overseas revenue and enhanced delivery capabilities [18][22]. Conclusion - The company is well-positioned for continued growth across its various business segments, with a strong order backlog and strategic investments planned for capacity expansion and new business development [2][3][16][19].